A clinical trial to study the effect of two drugs vatari guggulu and mahaushadhi kwatha in patients suffering with amavata (rheumatoid arthritis).

Phase 2

Conditions: Health Condition 1: null- Amavata (Rheumatoid arthritis)

Registration Number: CTRI/2018/05/014035

Lead Sponsor: Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Amavata with features of rheumatoid arthritis as specified in 2010 ACR-EULAR classification criteria for Rheumatoid arthritis with less than 5 years of chronicity (Parameters in ACR-EULAR criteria: Duration of symptoms, joint distribution, serology, acute phase reactants)

2. Patients aged between 20-60 years

3. Patients of either gender

4. Patient willing to participate in the study and ready to sign informed consent form

Exclusion Criteria

1.Hypertension, diabetes mellitus and other systemic disorders

2.Impaired renal, hepatic and cardiac function

3.Systemic arthritis (gout, tubercular arthritis, Systemic lupus erythematosus, psoriatic arthritis)

4.Swan neck deformity, Boutonniere deformity, rheumatic nodules

5. Pregnant and lactating woman

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. <br/ ><br>The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes <br/ ><br>Timepoint: Signs and symptoms of amavata (rheumatoid arthritis) will be assessed by giving suitable scoring at three intervals namely before, 7th day and 15th day of treatment. <br/ ><br>The disease activity of the patient will be assessed by disease activity score of 28 joints (DAS28), simple disease activity index (SDAI), acute phase reactants (Erythrocyte sedimentation rate and c-reactive protein) and early morning stiffness in minutes <br/ ><br>

Secondary Outcome Measures